Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31200467 | 1.00 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL26457840 | 0.90 | AR (0.81) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL19051364 | 0.88 | AR (0.79) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL24053088 | 0.87 | AR (0.79) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL17009410 | 0.85 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL25649387 | 0.85 | AR (0.74) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL17009418 | 0.82 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL17009407 | 0.82 | AR (1.00) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL22402845 | 0.82 | AR (0.69) | ARNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL22402841 | 0.82 | AR (0.69) | ARNPC1RAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408106-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-12-12 | — | — | US | disclosed |
| US-20240376118-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-11-14 | — | — | US | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-20240317734-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-09-26 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-06-27 | — | — | US | disclosed |
| WO-2024102810-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11981672-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | Montelino Therapeutics Inc. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2024-01-04 | — | — | US | disclosed |
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | MONTELINO THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20200282068-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | DBD THERAPEUTICS, LLC | 2020-09-10 | — | — | US | disclosed |
| WO-2020160295-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160295-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | MONTELINO THERAPEUTICS, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-07-03 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2017-06-29 | — | — | US | disclosed |
| WO-2015120543-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAIN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787778-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
| US-20240376118-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
| US-20200282068-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3994/4885RAB9A 3512/4885 |
| US-10011573-B2 | Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use | AR, SHBG, BRCA1 | AR 1/4885NPC1 2934/4885RAB9A 4667/4885 |
| US-20240207415-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
| US-20200239430-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3994/4885RAB9A 3512/4885 |
| US-20240002360-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3994/4885RAB9A 3512/4885 |
| US-20240408106-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
| US-20240317734-A1 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
| US-20170183319-A1 | HUMAN ANDROGEN RECEPTOR DNA-BINDING DOMAN (DBD) COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | AR, FSHR, ESRRB | AR 1/4885NPC1 1960/4885RAB9A 4089/4885 |
| US-11981672-B2 | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor | AR, ADRM1, PSMA3 | AR 1/4885NPC1 3776/4885RAB9A 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.